-
1
-
-
79960065486
-
-
note
-
Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):1920-1959.
-
(2011)
J Am Coll Cardiol
, vol.57
, Issue.19
, pp. 1920-1959
-
-
Wright, R.S.1
Anderson, J.L.2
Adams, C.D.3
-
2
-
-
34548545280
-
-
note
-
Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(7):e148-e304.
-
(2007)
Circulation
, vol.116
, Issue.7
-
-
Anderson, J.L.1
Adams, C.D.2
Antman, E.M.3
-
3
-
-
70450199115
-
-
note
-
Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205-2241.
-
(2009)
J Am Coll Cardiol
, vol.54
, Issue.23
, pp. 2205-2241
-
-
Kushner, F.G.1
Hand, M.2
Smith Jr., S.C.3
-
4
-
-
17844373254
-
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents
-
Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126-2130.
-
(2005)
JAMA
, vol.293
, Issue.17
, pp. 2126-2130
-
-
Iakovou, I.1
Schmidt, T.2
Bonizzoni, E.3
-
5
-
-
0038649988
-
Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity
-
Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908-2913.
-
(2003)
Circulation
, vol.107
, Issue.23
, pp. 2908-2913
-
-
Gurbel, P.A.1
Bliden, K.P.2
Hiatt, B.L.3
O'Connor, C.M.4
-
6
-
-
8344221349
-
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
-
Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109(25):3171-3175.
-
(2004)
Circulation
, vol.109
, Issue.25
, pp. 3171-3175
-
-
Matetzky, S.1
Shenkman, B.2
Guetta, V.3
-
7
-
-
33845451677
-
A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation
-
Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(1):66, e69-e16.
-
(2007)
Am Heart J
, vol.153
, Issue.1
-
-
Brandt, J.T.1
Payne, C.D.2
Wiviott, S.D.3
-
8
-
-
4444353174
-
Pharmacokinetics of clopidogrel after administration of a high loading dose
-
Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004;92(2):311-316.
-
(2004)
Thromb Haemost
, vol.92
, Issue.2
, pp. 311-316
-
-
Taubert, D.1
Kastrati, A.2
Harlfinger, S.3
-
9
-
-
33646732608
-
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
-
Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166-1173.
-
(2006)
Eur Heart J
, vol.27
, Issue.10
, pp. 1166-1173
-
-
Jernberg, T.1
Payne, C.D.2
Winters, K.J.3
-
10
-
-
37849002889
-
Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
-
Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29(1):21-30.
-
(2008)
Eur Heart J
, vol.29
, Issue.1
, pp. 21-30
-
-
Wallentin, L.1
Varenhorst, C.2
James, S.3
-
11
-
-
56849130022
-
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
-
Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol. 2008;52(24):1968-1977.
-
(2008)
J Am Coll Cardiol
, vol.52
, Issue.24
, pp. 1968-1977
-
-
Erlinge, D.1
Varenhorst, C.2
Braun, O.O.3
-
12
-
-
18144371221
-
The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting
-
Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005;45(9):1392-1396.
-
(2005)
J Am Coll Cardiol
, vol.45
, Issue.9
, pp. 1392-1396
-
-
Gurbel, P.A.1
Bliden, K.P.2
Hayes, K.M.3
Yoho, J.A.4
Herzog, W.R.5
Tantry, U.S.6
-
13
-
-
0020611507
-
Ticlopidine hydrochloride: Relationship between dose, kinetics, plasma concentration and effect on platelet function
-
Picard-Fraire C. Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function. Thromb Res Suppl. 1983;4:119-128.
-
(1983)
Thromb Res Suppl
, vol.4
, pp. 119-128
-
-
Picard-Fraire, C.1
-
14
-
-
68949130179
-
P2Y(12) inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical use
-
Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30(16):1964-1977.
-
(2009)
Eur Heart J
, vol.30
, Issue.16
, pp. 1964-1977
-
-
Wallentin, L.1
-
15
-
-
0032813891
-
Pharmacokinetic profile of 14C-labeled clopidogrel
-
Lins R, Broekhuysen J, Necciari J, Deroubaix X. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin Thromb Hemost. 1999;25(Suppl 2):29-33.
-
(1999)
Semin Thromb Hemost
, vol.25
, Issue.SUPPL. 2
, pp. 29-33
-
-
Lins, R.1
Broekhuysen, J.2
Necciari, J.3
Deroubaix, X.4
-
16
-
-
0032797781
-
Pharmacokinetics of clopidogrel
-
Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999;25(Suppl 2):25-28.
-
(1999)
Semin Thromb Hemost
, vol.25
, Issue.SUPPL. 2
, pp. 25-28
-
-
Caplain, H.1
Donat, F.2
Gaud, C.3
Necciari, J.4
-
17
-
-
64149125143
-
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
-
Ernest CS II, Small DS, Rohatagi S, et al. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. J Pharmacokinet Pharmacodyn. 2008;35(6):593-618.
-
(2008)
J Pharmacokinet Pharmacodyn
, vol.35
, Issue.6
, pp. 593-618
-
-
Ernest, C.S.I.I.1
Small, D.S.2
Rohatagi, S.3
-
18
-
-
27744516843
-
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial
-
von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112(19):2946-2950.
-
(2005)
Circulation
, vol.112
, Issue.19
, pp. 2946-2950
-
-
von Beckerath, N.1
Taubert, D.2
Pogatsa-Murray, G.3
Schomig, E.4
Kastrati, A.5
Schomig, A.6
-
19
-
-
36849074168
-
Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
-
Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25(4):357-374.
-
(2007)
Cardiovasc Drug Rev
, vol.25
, Issue.4
, pp. 357-374
-
-
Jakubowski, J.A.1
Winters, K.J.2
Naganuma, H.3
Wallentin, L.4
-
20
-
-
34247256797
-
Cytochrome P450 3 A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
-
Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3 A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81(5):735-741.
-
(2007)
Clin Pharmacol Ther
, vol.81
, Issue.5
, pp. 735-741
-
-
Farid, N.A.1
Payne, C.D.2
Small, D.S.3
-
21
-
-
0038508970
-
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin
-
Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31(1):53-59.
-
(2003)
Drug Metab Dispos
, vol.31
, Issue.1
, pp. 53-59
-
-
Clarke, T.A.1
Waskell, L.A.2
-
22
-
-
58749094444
-
Cytochrome p-450 polymorphisms and response to clopidogrel
-
Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.
-
(2009)
N Engl J Med
, vol.360
, Issue.4
, pp. 354-362
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
23
-
-
36348943475
-
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
-
Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429-2436.
-
(2007)
J Thromb Haemost
, vol.5
, Issue.12
, pp. 2429-2436
-
-
Brandt, J.T.1
Close, S.L.2
Iturria, S.J.3
-
24
-
-
34249053105
-
The disposition of prasugrel, a novel thienopyridine, in humans
-
Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35(7):1096-1104.
-
(2007)
Drug Metab Dispos
, vol.35
, Issue.7
, pp. 1096-1104
-
-
Farid, N.A.1
Smith, R.L.2
Gillespie, T.A.3
-
25
-
-
46449103184
-
The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2
-
Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos. 2008;36(7):1227-1232.
-
(2008)
Drug Metab Dispos
, vol.36
, Issue.7
, pp. 1227-1232
-
-
Williams, E.T.1
Jones, K.O.2
Ponsler, G.D.3
-
26
-
-
33645105318
-
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
-
Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34(4):600-607.
-
(2006)
Drug Metab Dispos
, vol.34
, Issue.4
, pp. 600-607
-
-
Rehmel, J.L.1
Eckstein, J.A.2
Farid, N.A.3
-
27
-
-
35548933800
-
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
-
Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852-1856.
-
(2007)
J Am Coll Cardiol
, vol.50
, Issue.19
, pp. 1852-1856
-
-
Storey, R.F.1
Husted, S.2
Harrington, R.A.3
-
28
-
-
33646261670
-
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin
-
Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038-1047.
-
(2006)
Eur Heart J
, vol.27
, Issue.9
, pp. 1038-1047
-
-
Husted, S.1
Emanuelsson, H.2
Heptinstall, S.3
Sandset, P.M.4
Wickens, M.5
Peters, G.6
-
29
-
-
0035085132
-
Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes
-
Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001;85(3):401-407.
-
(2001)
Thromb Haemost
, vol.85
, Issue.3
, pp. 401-407
-
-
Storey, R.F.1
Oldroyd, K.G.2
Wilcox, R.G.3
-
30
-
-
73149118496
-
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: First experience in patients
-
Gurbel PA, Bliden KP, Antonino MJ, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost. 2010;8(1):43-53.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.1
, pp. 43-53
-
-
Gurbel, P.A.1
Bliden, K.P.2
Antonino, M.J.3
-
31
-
-
37249068049
-
Platelet activation and atherothrombosis
-
Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482-2494.
-
(2007)
N Engl J Med
, vol.357
, Issue.24
, pp. 2482-2494
-
-
Davi, G.1
Patrono, C.2
-
32
-
-
0031916728
-
Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets
-
Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem. 1998;273(4):2030-2034.
-
(1998)
J Biol Chem
, vol.273
, Issue.4
, pp. 2030-2034
-
-
Jin, J.1
Daniel, J.L.2
Kunapuli, S.P.3
-
33
-
-
0031914973
-
Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets
-
Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998;273(4):2024-2029.
-
(1998)
J Biol Chem
, vol.273
, Issue.4
, pp. 2024-2029
-
-
Daniel, J.L.1
Dangelmaier, C.2
Jin, J.3
Ashby, B.4
Smith, J.B.5
Kunapuli, S.P.6
-
34
-
-
0344200064
-
Role of intracellular signaling events in ADP-induced platelet aggregation
-
Daniel JL, Dangelmaier C, Jin J, Kim YB, Kunapuli SP. Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost. 1999;82(4):1322-1326.
-
(1999)
Thromb Haemost
, vol.82
, Issue.4
, pp. 1322-1326
-
-
Daniel, J.L.1
Dangelmaier, C.2
Jin, J.3
Kim, Y.B.4
Kunapuli, S.P.5
-
35
-
-
34547655744
-
-
note
-
Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non- ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration wi th the Amer ican Col lege of Emergency Phys icians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1-e157.
-
(2007)
J Am Coll Cardiol
, vol.50
, Issue.7
-
-
Anderson, J.L.1
Adams, C.D.2
Antman, E.M.3
-
36
-
-
37349111065
-
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation- Thrombolysis in Myocardial Infarction 44 trial
-
Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation- Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923-2932.
-
(2007)
Circulation
, vol.116
, Issue.25
, pp. 2923-2932
-
-
Wiviott, S.D.1
Trenk, D.2
Frelinger, A.L.3
-
37
-
-
33645982865
-
High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
-
Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006;4(3):542-549.
-
(2006)
J Thromb Haemost
, vol.4
, Issue.3
, pp. 542-549
-
-
Cuisset, T.1
Frere, C.2
Quilici, J.3
-
38
-
-
34447636769
-
Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
-
Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5(8):1630-1636.
-
(2007)
J Thromb Haemost
, vol.5
, Issue.8
, pp. 1630-1636
-
-
Bonello, L.1
Paganelli, F.2
Arpin-Bornet, M.3
-
39
-
-
34250020766
-
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
-
Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49(24):2312-2317.
-
(2007)
J Am Coll Cardiol
, vol.49
, Issue.24
, pp. 2312-2317
-
-
Buonamici, P.1
Marcucci, R.2
Migliorini, A.3
-
40
-
-
0029782602
-
The efficacy and potency of antiplatelet activity of ticlopidine is increased by aspirin
-
Splawinska B, Kuzniar J, Malinga K, Mazurek AP, Splawinski J. The efficacy and potency of antiplatelet activity of ticlopidine is increased by aspirin. Int J Clin Pharmacol Ther. 1996;34(8):352-356.
-
(1996)
Int J Clin Pharmacol Ther
, vol.34
, Issue.8
, pp. 352-356
-
-
Splawinska, B.1
Kuzniar, J.2
Malinga, K.3
Mazurek, A.P.4
Splawinski, J.5
-
41
-
-
0032706553
-
Effects of ticlopidine or ticlopidine plus aspirin on platelet aggregation and ATP release in normal volunteers: Why aspirin improves ticlopidine antiplatelet activity
-
Altman R, Scazziota A, Rouvier J, Gonzalez C. Effects of ticlopidine or ticlopidine plus aspirin on platelet aggregation and ATP release in normal volunteers: why aspirin improves ticlopidine antiplatelet activity. Clin Appl Thromb Hemost. 1999;5(4):243-246.
-
(1999)
Clin Appl Thromb Hemost
, vol.5
, Issue.4
, pp. 243-246
-
-
Altman, R.1
Scazziota, A.2
Rouvier, J.3
Gonzalez, C.4
-
42
-
-
33748948717
-
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting
-
Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol. 2006;48(7):1339-1345.
-
(2006)
J Am Coll Cardiol
, vol.48
, Issue.7
, pp. 1339-1345
-
-
Cuisset, T.1
Frere, C.2
Quilici, J.3
-
43
-
-
33747874088
-
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial
-
Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48(5): 931-938.
-
(2006)
J Am Coll Cardiol
, vol.48
, Issue.5
, pp. 931-938
-
-
Montalescot, G.1
Sideris, G.2
Meuleman, C.3
-
44
-
-
7544239072
-
High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability
-
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J. 2004;25(21):1903-1910.
-
(2004)
Eur Heart J
, vol.25
, Issue.21
, pp. 1903-1910
-
-
Angiolillo, D.J.1
Fernandez-Ortiz, A.2
Bernardo, E.3
-
45
-
-
4944261759
-
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy
-
Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation. 2004;110(14):1916-1919.
-
(2004)
Circulation
, vol.110
, Issue.14
, pp. 1916-1919
-
-
Kastrati, A.1
von Beckerath, N.2
Joost, A.3
Pogatsa-Murray, G.4
Gorchakova, O.5
Schomig, A.6
-
46
-
-
67651173161
-
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
-
Michelson AD, Frelinger AL III, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009;30(14):1753-1763.
-
(2009)
Eur Heart J
, vol.30
, Issue.14
, pp. 1753-1763
-
-
Michelson, A.D.1
Frelinger III, A.L.2
Braunwald, E.3
-
47
-
-
33745699564
-
The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects
-
Jakubowski JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006;47(3):377-384.
-
(2006)
J Cardiovasc Pharmacol
, vol.47
, Issue.3
, pp. 377-384
-
-
Jakubowski, J.A.1
Payne, C.D.2
Brandt, J.T.3
-
48
-
-
36348977461
-
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to highdose clopidogrel
-
Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to highdose clopidogrel. J Cardiovasc Pharmacol. 2007;50(5):555-562.
-
(2007)
J Cardiovasc Pharmacol
, vol.50
, Issue.5
, pp. 555-562
-
-
Payne, C.D.1
Li, Y.G.2
Small, D.S.3
-
49
-
-
77955638355
-
-
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons, 2010
-
Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010 2010;56(4):321-341.
-
(2010)
J Am Coll Cardiol.
, vol.56
, Issue.4
, pp. 321-341
-
-
Holmes Jr., D.R.1
Dehmer, G.J.2
Kaul, S.3
Leifer, D.4
O'Gara, P.T.5
Stein, C.M.6
-
51
-
-
0038291914
-
Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement
-
Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89(5):783-787.
-
(2003)
Thromb Haemost
, vol.89
, Issue.5
, pp. 783-787
-
-
Muller, I.1
Besta, F.2
Schulz, C.3
Massberg, S.4
Schonig, A.5
Gawaz, M.6
-
52
-
-
74049095574
-
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
-
Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G. Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag. 2009;5:965-972.
-
(2009)
Vasc Health Risk Manag
, vol.5
, pp. 965-972
-
-
Sharma, R.K.1
Reddy, H.K.2
Singh, V.N.3
Sharma, R.4
Voelker, D.J.5
Bhatt, G.6
-
53
-
-
56749183852
-
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
-
Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894-1909.
-
(2008)
Circulation
, vol.118
, Issue.18
, pp. 1894-1909
-
-
Bhatt, D.L.1
Scheiman, J.2
Abraham, N.S.3
-
54
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
-
(2007)
N Engl J Med
, vol.357
, Issue.20
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
-
55
-
-
70249139788
-
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials
-
O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-997.
-
(2009)
Lancet
, vol.374
, Issue.9694
, pp. 989-997
-
-
O'Donoghue, M.L.1
Braunwald, E.2
Antman, E.M.3
-
56
-
-
77957157470
-
The Interaction between clopidogrel and proton pump inhibtors (PPI): Is there any clinical relevance
-
Sharma RK, Reddy HK, Sharma R, et al. The Interaction between clopidogrel and proton pump inhibtors (PPI): is there any clinical relevance. Clinical Pharmacology: Advances and Applications. 2011;2:155-162.
-
(2011)
Clinical Pharmacology: Advances and Applications
, vol.2
, pp. 155-162
-
-
Sharma, R.K.1
Reddy, H.K.2
Sharma, R.3
-
57
-
-
69249219296
-
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
-
Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
-
(2009)
JAMA
, vol.302
, Issue.8
, pp. 849-857
-
-
Shuldiner, A.R.1
O'Connell, J.R.2
Bliden, K.P.3
-
58
-
-
58749090547
-
Genetic determinants of response to clopidogrel and cardiovascular events
-
Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.
-
(2009)
N Engl J Med
, vol.360
, Issue.4
, pp. 363-375
-
-
Simon, T.1
Verstuyft, C.2
Mary-Krause, M.3
-
59
-
-
77955638355
-
-
note
-
Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/ AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning" A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321-341.
-
(2010)
J Am Coll Cardiol
, vol.56
, Issue.4
, pp. 321-341
-
-
Holmes Jr., D.R.1
Dehmer, G.J.2
Kaul, S.3
Leifer, D.4
O'Gara, P.T.5
Stein, C.M.6
-
60
-
-
27644536235
-
Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POSTSTENTING Study
-
Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POSTSTENTING Study. J Am Coll Cardiol. 2005;46(10):1820-1826.
-
(2005)
J Am Coll Cardiol
, vol.46
, Issue.10
, pp. 1820-1826
-
-
Gurbel, P.A.1
Bliden, K.P.2
Guyer, K.3
-
61
-
-
33846837282
-
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate?
-
Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49(6):657-666.
-
(2007)
J Am Coll Cardiol
, vol.49
, Issue.6
, pp. 657-666
-
-
Bliden, K.P.1
di Chiara, J.2
Tantry, U.S.3
Bassi, A.K.4
Chaganti, S.K.5
Gurbel, P.A.6
-
62
-
-
73449106079
-
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease
-
Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation. 2009;120(22):2214-2221.
-
(2009)
Circulation
, vol.120
, Issue.22
, pp. 2214-2221
-
-
Migliorini, A.1
Valenti, R.2
Marcucci, R.3
-
63
-
-
44949173754
-
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
-
Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29(8):992-1000.
-
(2008)
Eur Heart J
, vol.29
, Issue.8
, pp. 992-1000
-
-
Price, M.J.1
Endemann, S.2
Gollapudi, R.R.3
-
64
-
-
59849120163
-
Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up
-
Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119(2):237-242.
-
(2009)
Circulation
, vol.119
, Issue.2
, pp. 237-242
-
-
Marcucci, R.1
Gori, A.M.2
Paniccia, R.3
-
65
-
-
78049417758
-
Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: A prospective registry
-
El Ghannudi S, Ohlmann P, Meyer N, et al. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. JACC. Cardiovascular interventions. 2010;3(6):648-656.
-
(2010)
JACC. Cardiovascular Interventions
, vol.3
, Issue.6
, pp. 648-656
-
-
El Ghannudi, S.1
Ohlmann, P.2
Meyer, N.3
-
66
-
-
77249113768
-
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
-
Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754-762.
-
(2010)
JAMA
, vol.303
, Issue.8
, pp. 754-762
-
-
Breet, N.J.1
van Werkum, J.W.2
Bouman, H.J.3
-
67
-
-
0037145863
-
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
-
Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411-2420.
-
(2002)
JAMA
, vol.288
, Issue.19
, pp. 2411-2420
-
-
Steinhubl, S.R.1
Berger, P.B.2
Mann III, J.T.3
-
68
-
-
70149101223
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
-
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
-
(2009)
N Engl J Med
, vol.361
, Issue.11
, pp. 1045-1057
-
-
Wallentin, L.1
Becker, R.C.2
Budaj, A.3
-
69
-
-
29344466941
-
Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance
-
Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006;47(1):27-33.
-
(2006)
J Am Coll Cardiol
, vol.47
, Issue.1
, pp. 27-33
-
-
Lev, E.I.1
Patel, R.T.2
Maresh, K.J.3
-
70
-
-
35549008493
-
Platelet function monitoring in patients with coronary artery disease
-
Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50(19):1822-1834.
-
(2007)
J Am Coll Cardiol
, vol.50
, Issue.19
, pp. 1822-1834
-
-
Gurbel, P.A.1
Becker, R.C.2
Mann, K.G.3
Steinhubl, S.R.4
Michelson, A.D.5
-
71
-
-
84857182334
-
Effect of Cilostazol adding or clopidogrel doubling on platelet function with diabetes and coronary artery disease on dual antiplatelet therapy
-
A113.E 1058
-
Ha S. Effect of Cilostazol adding or clopidogrel doubling on platelet function with diabetes and coronary artery disease on dual antiplatelet therapy. J Am Coll Cardiol. 2010;55(A113.E 1058).
-
(2010)
J Am Coll Cardiol
, vol.55
-
-
Ha, S.1
-
72
-
-
77950555307
-
Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: The OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study
-
Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol. 2010;55(16):1671-1678.
-
(2010)
J Am Coll Cardiol
, vol.55
, Issue.16
, pp. 1671-1678
-
-
Gajos, G.1
Rostoff, P.2
Undas, A.3
Piwowarska, W.4
-
73
-
-
79959865823
-
-
note
-
Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):e215-367.
-
(2011)
J Am Coll Cardiol
, vol.57
, Issue.19
-
-
Wright, R.S.1
Anderson, J.L.2
Adams, C.D.3
-
74
-
-
77955638355
-
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning". A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
-
Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning". A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. J Am Coll Cardiol. 2010;56(4):321-341.
-
(2010)
J Am Coll Cardiol
, vol.56
, Issue.4
, pp. 321-341
-
-
Holmes Jr., D.R.1
Dehmer, G.J.2
Kaul, S.3
Leifer, D.4
O'Gara, P.T.5
Stein, C.M.6
|